drugset / Trial / NCT05473468

Single Dose Study To Study The Absorption, Metabolism And Excretion Of Famitinib

NCT05473468

Phase 1 Unknown 6 enrolled Jiangsu HengRui Medicine Co., Ltd.
NaSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to evaluate the excretion balance, metabolic profile and the routes of excretion of famitinib in healthy adult male subjects.

Timeline

Start
2022-08-26
Primary completion
2022-11
Completion
2022-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Famitinib Small molecule 25 mg Oral

Indications

No indication recorded.